Table 2.

Overall and disease-free survival in patients undergoing CRS/HIPEC [n = 177]

	Total [n = 177]	No ascites [n = 135]	Ascites [n = 42]	p-Value
OS
Median (95% CI)  3-year (%)  5-year (%)	27.0 (22.5–31.5) 39.2 20.9	27.0 (22.4–31.6) 37.9 19.8	25.0 (9.4–40.6) 44.1 28.0	0.536
DFS
Median (95% CI)  3-year (%)  5-year (%)	9 (7.4–10.6) 14.5 7.9	9 (7.2–10.8) 13.5 9.4	10 (7.1–12.9) 18.9 4.7	0.814

CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal metastases, OS overall survival, DFS disease-free survival, CI confidence interval